Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: Frequency of expression and correlation with prognostic parameters

Modern Pathology

Volumn 13, Issue 4, 2000, Pages 459-465

  Busam, Klaus J ^a,c   Iversen, Kristin ^b   Berwick, Marianne ^a   Spagnoli, Guilio C ^a   Old, Lloyd J ^a   Jungbluth, Achim A ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; MAGE; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

MELANOMA ASSOCIATED ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 57 B; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0033994480     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880078     Document Type: Article

References (42)

1. Boon T, Old LJ. Tumor antigens. Cur Opin Immunol 1997;9: 681-3.
2. Boon T, Vanderbruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996:183:725-9.
3. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995; 145:229-50.
4. Van der Bruggen P, Traversari C, Chômez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
5. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992; 53:145-52.
6. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide induced by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994:24:3038-43.
7. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994:40:360-9.
8. Gaugler B, Van den Eynde B, Brasseur F, Boon T. Human gene MAGE-3 codes for antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994:179: 921-30.
9. Van den Eynde B, Peelers O, DeBacker O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on human melanoma. J Exp Med 1995:182:689-98.
10. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995:63:375-80.
11. Lucas S, DeSmet C, Arden KC, Viars CS, Lethe B, Lurquin C, et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 1998:58:743-52.
12. Jurk M, Kremmer E, Schwarz U, Forster R, Wmnacker FL. MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. Int J Cancer 1998:75:762-6.
13. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995:55:2236-9.
14. Sahin U, Turect O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, et al. Expression of multiple cancer/testis antigens in breast cancer arid melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998:78:387-9.
15. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small cell lung carcinomas. Int J Cancer 1994:56:826-9.
16. Mori M, Inoue H, Mimori K, Shibuta K, Baba K, Nakashima H, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996:224:183-8.
17. Patard J-J, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, et al Expression of MAGE genes in transitional cell carcinomas of the urinary bladder. Int J Cancer 1995;64: 60-4.
18. Hofbauer GFL, Schaefer C, Noppen C, Boeni R, Kamarashev, Nestle FO, et al. MAGE-3 immunoreactivity in formalinfixed, paraffin-embedded primary and metastatic melanoma. Am J Pathol 1997:151:1549-53.
19. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995:63:883-5.
20. Maeurer MJ, Storkus VVJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996;6:ll-24.
21. Gattoni-Celli S, Cole DJ. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol 1996:23:754-8.
22. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996;47:481-91.
23. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970:172:902-8.
24. Clark WH Jr, Elder DE, Guerry DP IV, Braitman LE, Trock BJ, Schultz D, et al Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
25. Elder DE, Guerry DIV, VanHorn M, Hurwitz S, Zehngebot L, Goldman LI, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985:56:413-8.
26. Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Elder DE, Murphy GF, editors. Melanocytic tumors of the skin. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1990. pp. 103-205.
27. Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17:443-50.
28. McGovern VJ, Mihm MC Jr, Bailly C, Booth JC, Clark WH Jr, Cochran AJ, et al. The classification of malignant melanoma and its histologie reporting. Cancer 1973:32:1446-57.
29. American Joint Committee on Cancer. Manual for staging of cancer (4th ed.), Philadelphia: J.B. Lippincott; 1992. pp. 143-8.
30. Chen YT, Cure AO, Tsang S, Stocken E, Jager E, Knuth A, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sei U S A 1998;95:6919-23.
31. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A, et al. Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expression MART1/Melan-A, gplOO and tyrosinase genes: a study in an un-selected group of HLA-A2.1 -positive patients. Int J Cancer 1995;65:309-15.
32. Busam KJ, Iversen K, Coplan KA, Old LJ, Stocken E, Chen YT, et al. Immunoreactivity for A103, an antibody to Melan-A (MART-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998;22:57-63.
33. Busam KJ, Chen YT, Old LJ, Stocken E, Iversen K, Coplan KA, et al. Expression of Melan-A (MART-1) in benign melanocytic nevi and primary malignant melanoma. Am J Surg Pathol 1998:22:976-82.
34. Chen YT, Stocken E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sei U S A 1995;92: 8125-9.
35. Chen YT, Stocken E, Jungbluth AA, Tsang S, Coplan KA, Scanlan MJ, et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sei U. S. A. 1996;93: 5915-9.
36. Jungbluth AA, Busam KJ, Chen TY, Stocken E, Coplan KA, Iversen K, etal. A103-an anti-Melan-A/MART-1 monoclonal antibody for the detection of malignant melanoma in paraffin embedded tissues. Am J Surg Pathol 1998;22:595-602.
37. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, et al. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple cutaneous métastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998:77:200-4.
38. McGovem VJ, Shaw HM, Milton GW, Farago GA. Lymphocytic infiltration and survival in malignant melanoma. In: Ackermann AB, editor. Pathology of malignant melanoma: Masson monographs in dermatopathology. New York: Masson Publishing; 1981. pp. 341-4.
39. Mansen MG, McCarten AB. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am J Surg 1974;128:557-61.
40. Clémente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996:77:1303-10.
41. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to Interferon treatment. Br J Cancer 1996:74:670-6.
42. Mihm MC Jr, Clémente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma métastases: a histologie prognostic indicator and an expression of local immune response. Lab Invest 1996:74:43-7.